Author
Listed:
- Arne Matthys
(VIB Center for Medical Biotechnology, VIB
Ghent University)
- Jan Felix
(Ghent University
VIB-UGent Center for Inflammation Research)
- Joao Paulo Portela Catani
(VIB Center for Medical Biotechnology, VIB
Ghent University)
- Kenny Roose
(VIB Center for Medical Biotechnology, VIB
Ghent University)
- Wim Nerinckx
(VIB Center for Medical Biotechnology, VIB
Ghent University)
- Benthe Buyten
(VIB Center for Medical Biotechnology, VIB
Ghent University)
- Daria Fijalkowska
(VIB Center for Medical Biotechnology, VIB
Ghent University)
- Nico Callewaert
(VIB Center for Medical Biotechnology, VIB
Ghent University)
- Savvas N. Savvides
(Ghent University
VIB-UGent Center for Inflammation Research)
- Xavier Saelens
(VIB Center for Medical Biotechnology, VIB
Ghent University)
Abstract
Influenza B viruses are antigenically diverse and contribute significantly to the annual influenza burden. Here we report influenza B virus neutralizing single-domain antibodies that target highly conserved regions of the hemagglutinin and neuraminidase. Structural studies by single particle electron cryo-microscopy (cryo-EM) revealed that one of these single-domain antibodies prevents the conformational transition of the viral hemagglutinin to the post-fusion state by targeting a quaternary epitope spanning two protomers in the hemagglutinin-stem region. A second single-domain antibody broadly inhibits influenza B neuraminidase activity, including an oseltamivir-resistant neuraminidase, and its complex with neuraminidase elucidated by single particle cryo-EM established that it binds to residues in the neuraminidase catalytic site. Head-to-tail fusions of these single-domain antibodies led to bispecific binders that further improved the neutralization breadth and potency against influenza B viruses. These single-domain antibodies, fused to a human IgG1-Fc domain, fully protected female mice against an otherwise lethal influenza B virus challenge. Our findings underscore the potential of engineered single-domain antibodies to help control influenza B virus infections.
Suggested Citation
Arne Matthys & Jan Felix & Joao Paulo Portela Catani & Kenny Roose & Wim Nerinckx & Benthe Buyten & Daria Fijalkowska & Nico Callewaert & Savvas N. Savvides & Xavier Saelens, 2025.
"Single-domain antibodies directed against hemagglutinin and neuraminidase protect against influenza B viruses,"
Nature Communications, Nature, vol. 16(1), pages 1-19, December.
Handle:
RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-60232-3
DOI: 10.1038/s41467-025-60232-3
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-60232-3. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.